{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:04:05Z","timestamp":1789495445499,"version":"build-2803163510"},"reference-count":42,"publisher":"Becaris Publishing Limited","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Dexamethasone was shown to decrease the mortality in coronavirus disease-2019 (COVID-19) recently. Use of corticosteroids was harmful in other coronavirus infections previously. WHO\u00a0recommended against routine use of corticosteroids in COVID-19. In view of these, we reviewed the evidence about the use of corticosteroids in virus-induced acute respiratory distress syndrome (ARDS). Corticosteroids are beneficial in ARDS regardless of etiology. However, they increased the mortality rate in influenza-associated ARDS. In SARS and the Middle East respiratory syndrome, corticosteroids increased the mortality, delayed the viral clearance\u00a0and increased the length of hospital stay. In the case of COVID-19, the available evidence from retrospective and observational studies is inconclusive about the corticosteroid use. Low-dose therapies appear to be effective. Evidence from a randomized control study found dexamethasone is effective in decreasing mortality in severe COVID-19 cases. More studies are needed to validate the benefit of corticosteroids in COVID-19.<\/jats:p>","DOI":"10.2217\/cer-2020-0146","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T14:27:28Z","timestamp":1606487248000},"page":"1247-1254","source":"Crossref","is-referenced-by-count":23,"title":["Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019"],"prefix":"10.57264","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-3901","authenticated-orcid":false,"given":"Mohamed","family":"Rafiullah","sequence":"first","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-1262","authenticated-orcid":false,"given":"Khalid","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_3_3_2","first-page":"1","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: an update on the status","volume":"7","author":"Guo Y-R","year":"2020","unstructured":"Guo Y-R, Cao Q-D, Hong Z-S The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: an update on the status. Mil. Med. Res. 7(1), 1\u201310 (2020).","journal-title":"Mil. Med. Res."},{"issue":"18","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan W","year":"2020","unstructured":"Guan W, Ni Z, Hu Y Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382(18), 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13054-020-02911-9","article-title":"Acute respiratory failure in COVID-19: is it \u201ctypical\u201d ARDS?","volume":"24","author":"Li X","year":"2020","unstructured":"Li X, Ma X. Acute respiratory failure in COVID-19: is it \u201ctypical\u201d ARDS? Crit. Care 24(1), 198 (2020).","journal-title":"Crit. Care"},{"issue":"2","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/JVI.02576-13","article-title":"Inhibition of NF-\u03baB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival","volume":"88","author":"DeDiego ML","year":"2014","unstructured":"DeDiego ML, Nieto-Torres JL, Regla-Nava JA Inhibition of NF-\u03baB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol. 88(2), 913\u2013924 (2014).","journal-title":"J. Virol."},{"issue":"12","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan JF-W","year":"2015","unstructured":"Chan JF-W, Yao Y, Yeung M-L Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212(12), 1904\u20131913 (2015).","journal-title":"J. Infect. Dis."},{"issue":"6","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi YM","year":"2018","unstructured":"Arabi YM, Mandourah Y, Al-Hameed F Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am. J. Respir. Crit. Care Med. 197(6), 757\u2013767 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman LJ","year":"2006","unstructured":"Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 3(9), e343 (2006).","journal-title":"PLoS Med."},{"issue":"12","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa040419","article-title":"Avian influenza A (H5N1) in 10 patients in Vietnam","volume":"350","author":"Tran TH","year":"2004","unstructured":"Tran TH, Nguyen TL, Nguyen TD Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350(12), 1179\u20131188 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1378\/chest.129.1.156","article-title":"Avian influenza virus infections in humans","volume":"129","author":"Wong SSY","year":"2006","unstructured":"Wong SSY, Yuen K-Y. Avian influenza virus infections in humans. Chest 129(1), 156\u2013168 (2006).","journal-title":"Chest"},{"issue":"6","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1164\/rccm.201712-2371ED","article-title":"Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection","volume":"197","author":"Hui DS","year":"2018","unstructured":"Hui DS. Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection. Am. J. Respir. Crit. Care Med. 197(6), 700\u2013701 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jinf.2004.09.008","article-title":"The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study","volume":"51","author":"Auyeung TW","year":"2005","unstructured":"Auyeung TW, Lee JSW, Lai WK The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J. Infect. 51(2), 98\u2013102 (2005).","journal-title":"J. Infect."},{"key":"e_1_3_3_14_2","unstructured":"WHO. Clinical management of COVID-19 (2020). www.who.int\/publications\/i\/item\/clinical-management-of-covid-19"},{"issue":"6","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams DM","year":"2018","unstructured":"Williams DM. Clinical pharmacology of corticosteroids. Respir. Care 63(6), 655\u2013670 (2018).","journal-title":"Respir. Care"},{"issue":"5","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi Y","year":"2020","unstructured":"Shi Y, Wang Y, Shao C COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 27(5), 1451\u20131454 (2020).","journal-title":"Cell Death Differ."},{"issue":"5","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00296-020-04570-z","article-title":"Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs","volume":"40","author":"Georgiev T","year":"2020","unstructured":"Georgiev T. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol. Int. 40(5), 825\u2013826 (2020).","journal-title":"Rheumatol. Int."},{"issue":"1","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"e000420","DOI":"10.1136\/bmjresp-2019-000420","article-title":"Guidelines on the management of acute respiratory distress syndrome","volume":"6","author":"Griffiths MJD","year":"2019","unstructured":"Griffiths MJD, McAuley DF, Perkins GD Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir. Res. 6(1), e000420 (2019).","journal-title":"BMJ Open Respir. Res."},{"issue":"4","key":"e_1_3_3_19_2","first-page":"276","article-title":"Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials","volume":"130","author":"Mammen MJ","year":"2020","unstructured":"Mammen MJ, Aryal K, Alhazzani W, Alexander PE. Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. Polish Arch. Intern. Med. 130(4), 276\u2013286 (2020).","journal-title":"Polish Arch. Intern. Med."},{"issue":"6","key":"e_1_3_3_20_2","first-page":"4637","article-title":"Effect of different doses and time-courses of corticosteroid treatment in patients with acute respiratory distress syndrome: a meta-analysis","volume":"18","author":"Sun S","year":"2019","unstructured":"Sun S, Liu D, Zhang H, Zhang X, Wan B. Effect of different doses and time-courses of corticosteroid treatment in patients with acute respiratory distress syndrome: a meta-analysis. Exp. Ther. Med. 18(6), 4637\u20134644 (2019).","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"e_1_3_3_21_2","first-page":"4913","article-title":"Effect of glucocorticoids on mortality in patients with acute respiratory distress syndrome: a meta-analysis","volume":"18","author":"Zhao Q","year":"2019","unstructured":"Zhao Q, Shi J, Hu R, Li Q, Zhang C, Li J. Effect of glucocorticoids on mortality in patients with acute respiratory distress syndrome: a meta-analysis. Exp. Ther. Med. 18(6), 4913\u20134920 (2019).","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3892\/etm.2017.4154","article-title":"Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: a meta-analysis of randomized controlled trials","volume":"13","author":"Yang ZG","year":"2017","unstructured":"Yang ZG, Lei XL, Li XL. Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Exp. Ther. Med. 13(4), 1215\u20131224 (2017).","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"e_1_3_3_23_2","first-page":"1","article-title":"Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis","volume":"10","author":"Zhou Y","year":"2020","unstructured":"Zhou Y, Fu X, Liu X Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Sci. Rep. 10(1), 1\u201310 (2020).","journal-title":"Sci. Rep."},{"issue":"1","key":"e_1_3_3_24_2","first-page":"1","article-title":"The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis","volume":"23","author":"Ni YN","year":"2019","unstructured":"Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit. Care 23(1), 1\u20139 (2019).","journal-title":"Crit. Care"},{"issue":"10","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.cmi.2015.06.022","article-title":"Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis","volume":"21","author":"Yang JW","year":"2015","unstructured":"Yang JW, Fan LC, Miao XY Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. Clin. Microbiol. Infect. 21(10), 956\u2013963 (2015).","journal-title":"Clin. Microbiol. Infect."},{"issue":"2","key":"e_1_3_3_26_2","first-page":"CD010406","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"2","author":"Lansbury L","year":"2019","unstructured":"Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst. Rev. 2(2), CD010406 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1086\/591708","article-title":"Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness","volume":"198","author":"Morens DM","year":"2008","unstructured":"Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198(7), 962\u2013970 (2008).","journal-title":"J. Infect. Dis."},{"issue":"6","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1097\/CCM.0000000000001616","article-title":"Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia","volume":"44","author":"Cao B","year":"2016","unstructured":"Cao B, Gao H, Zhou B Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit. Care Med. 44(6), e318\u2013328 (2016).","journal-title":"Crit. Care Med."},{"issue":"6","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41375-020-0848-3","article-title":"Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis","volume":"34","author":"Li H","year":"2020","unstructured":"Li H, Chen C, Hu F Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia 34(6), 1503\u20131511 (2020).","journal-title":"Leukemia"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jinf.2020.03.062","article-title":"The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis","volume":"81","author":"Yang Z","year":"2020","unstructured":"Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J. Infect. 81, 13\u201320 (2020).","journal-title":"J. Infect."},{"issue":"4","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee N","year":"2004","unstructured":"Lee N, Allen Chan KC, Hui DS Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J. Clin. Virol. 31(4), 304\u2013309 (2004).","journal-title":"J. Clin. Virol."},{"key":"e_1_3_3_32_2","article-title":"Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis","author":"Zhang JJY","year":"2020","unstructured":"Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin. Infect. Dis. doi: 10.1093\/cid\/ciaa576 (2020) (Epub ahead of print).","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.00170","article-title":"Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature","volume":"7","author":"Veronese N","year":"2020","unstructured":"Veronese N, Demurtas J, Yang L Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front. Med. 7(April), 1\u20136 (2020).","journal-title":"Front. Med."},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"104872","DOI":"10.1016\/j.phrs.2020.104872","article-title":"Efficacy and safety of current therapeutic options for COVID-19 \u2013 lessons to be learnt from SARS and MERS epidemic: a systematic review and meta-analysis","volume":"157","author":"Zhong H","year":"2020","unstructured":"Zhong H, Wang Y, Zhang Z-L Efficacy and safety of current therapeutic options for COVID-19 \u2013 lessons to be learnt from SARS and MERS epidemic: a systematic review and meta-analysis. Pharmacol. Res. 157, 104872 (2020).","journal-title":"Pharmacol. Res."},{"key":"e_1_3_3_35_2","article-title":"Early short course corticosteroids in hospitalized patients with COVID-19","author":"Fadel R","year":"2020","unstructured":"Fadel R, Morrison AR, Vahia A Early short course corticosteroids in hospitalized patients with COVID-19. Clin. Infect. Dis. doi: 10.1093\/cid\/ciaa601 (2020) (Epub ahead of print).","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.5694\/mja2.50577","article-title":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)","volume":"212","author":"Zha L","year":"2020","unstructured":"Zha L, Li S, Pan L Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust. 212(9), 416\u2013420 (2020).","journal-title":"Med. J. Aust."},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26052","article-title":"Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old","author":"Gong Y","year":"2020","unstructured":"Gong Y, Guan L, Jin Z, Chen S, Xiang G, Gao B. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old. J. Med. Virol. doi: 10.1002\/jmv.26052 (2020) (Epub ahead of print).","journal-title":"J. Med. Virol."},{"issue":"1","key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jinf.2020.03.039","article-title":"Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19","volume":"81","author":"Fang X","year":"2020","unstructured":"Fang X, Mei Q, Yang T Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J. Infect. 81(1), 147\u2013178 (2020).","journal-title":"J. Infect."},{"issue":"6","key":"e_1_3_3_39_2","first-page":"39","article-title":"Short-term dexamethasone in Sars-CoV-2 patients","volume":"103","author":"Selvaraj V","year":"2020","unstructured":"Selvaraj V, Dapaah-Afriyie K, Finn A, Flanigan TP. Short-term dexamethasone in Sars-CoV-2 patients. R. I. Med. J. (2013) 103(6), 39\u201343 (2020).","journal-title":"R. I. Med. J. (2013)"},{"key":"e_1_3_3_40_2","article-title":"High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19","author":"Li S","year":"2020","unstructured":"Li S, Hu Z, Song X. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19. Clin. Infect. Dis. doi: 10.1093\/cid\/ciaa829 (2020) (Epub ahead of print).","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_41_2","article-title":"Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis","author":"Yuan M","year":"2020","unstructured":"Yuan M, Xu X, Xia D Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock doi:10.1097\/SHK.0000000000001574 (2020) (Epub ahead of print).","journal-title":"Shock"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022926","article-title":"Dexamethasone in hospitalized patients with Covid-19:preliminary report","author":"The RECOVERY Collaborative Group","year":"2020","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19:preliminary report. N. Engl. J. Med. doi:10.1056\/NEJMoa2021436 (2020) (Epub ahead of print).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_43_2","doi-asserted-by":"crossref","first-page":"m2512","DOI":"10.1136\/bmj.m2512","article-title":"COVID-19: demand for dexamethasone surges as RECOVERY trial publishes preprint","volume":"369","author":"Mahase E","year":"2020","unstructured":"Mahase E. COVID-19: demand for dexamethasone surges as RECOVERY trial publishes preprint. BMJ 369, m2512 (2020).","journal-title":"BMJ"},{"issue":"6","key":"e_1_3_3_44_2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 diabetes","volume":"31","author":"Zhu L","year":"2020","unstructured":"Zhu L, She ZG, Cheng X Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 diabetes. Cell Metab. 31(6), 1068\u20131077.e3 (2020).","journal-title":"Cell Metab."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:20:44Z","timestamp":1679232044000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.2217\/cer-2020-0146"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0146","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}